Normunity

About:

Normunity develops precision immuno-oncology medicines that enable normal immunity against cancer.

Website: https://normunity.com

Twitter/X: normunity

Top Investors: Canaan Partners, OUP (Osage University Partners), Taiho Ventures, Sanofi Ventures

Description:

Normunity is a biotechnology company creating a new class of precision immuno-oncology medicines, called immune normalizers, that target novel mechanisms that free the body’s normal immunity against cancer. Based on an ongoing, interactive academic-biotech alliance with the lab of Dr. Lieping Chen at Yale School of Medicine, Normunity is targeting newly-discovered mechanisms of immune disruption in cancer based on proprietary discovery platforms that elucidate the complex interactions between human cancer and the immune system. The company is advancing an emerging pipeline of immune normalizers, including initial drug programs that target mechanisms that drive the exclusion of T-cells from immune-sensitive tumors and other mechanisms that are barriers to normal immune function in cancer. Normunity is located in Boston, Massachusetts and West Haven, Connecticut.